{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:09:48Z","timestamp":1790111388665,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cientifico e Tecnologico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/200.815\/2021"],"award-info":[{"award-number":["E-26\/200.815\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115132","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:41:53Z","timestamp":1780501313000},"page":"115132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lipoxin A4 (LXA4) versus Nanolipoxin A4 (Nano-LXA4) for osteosarcoma"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9088-6671","authenticated-orcid":false,"given":"Nat\u00e1lia Cristina","family":"Gomes-da-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-7524","authenticated-orcid":false,"given":"Amanda","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Meohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Facchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila Alessandra","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Magalh\u00e3es","family":"Rebelo Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Ricci-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre B.A.","family":"Fechine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thereza Christina","family":"Barja-Fidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9612-0063","authenticated-orcid":false,"given":"Elaine Cruz","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-481X","authenticated-orcid":false,"given":"Ralph","family":"Santos-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejpb.2026.115132_b0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/diagnostics15030266","article-title":"Clinical and pathological profile of children and adolescents with osteosarcoma","volume":"15","author":"Ivan","year":"2025","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejpb.2026.115132_b0010","article-title":"Osteosarcoma: a comprehensive review of management and treatment strategies","volume":"49","author":"Jafari","year":"2020","journal-title":"Ann. Diagnost. Pathol."},{"issue":"41","key":"10.1016\/j.ejpb.2026.115132_b0015","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1038\/sj.onc.1210404","article-title":"RB1 and TP53 pathways in radiation-induced sarcomas","volume":"26","author":"Gonin-Laurent","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115132_b0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/07357907.2020.1768401","article-title":"Epidemiology and risk factors of osteosarcoma","volume":"38","author":"Sadykova","year":"2020","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ejpb.2026.115132_b0025","article-title":"European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma","volume":"2","author":"Van Ewijk","year":"2023","journal-title":"EJC Paediatr. Oncol."},{"issue":"19","key":"10.1016\/j.ejpb.2026.115132_b0030","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.3390\/jcm13195710","article-title":"Imaging of osteosarcoma: presenting findings, metastatic patterns, and features related to prognosis","volume":"13","author":"Cromb\u00e9","year":"2024","journal-title":"JCM"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115132_b0035","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s12672-025-02208-9","article-title":"Systemic strategies for osteosarcoma: advances and future directions","volume":"16","author":"Morya","year":"2025","journal-title":"Discov. Oncol."},{"issue":"51","key":"10.1016\/j.ejpb.2026.115132_b0040","doi-asserted-by":"crossref","first-page":"21134","DOI":"10.1073\/pnas.1202906109","article-title":"Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor","volume":"109","author":"Pamplona","year":"2012","journal-title":"PNAS"},{"issue":"16","key":"10.1016\/j.ejpb.2026.115132_b0045","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/cells14161244","article-title":"Lipoxins as modulators of diseases","volume":"14","author":"Saqib","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ejpb.2026.115132_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117662","article-title":"Eicosanoids and Inflammation: a delicate balance of Pro-Inflammatory and Pro-Resolving mediators","volume":"245","author":"Park","year":"2026","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115132_b0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/acsphyschemau.5c00008","article-title":"ALX\/FPR2 receptor activation by inflammatory (fMLFII) and pro-resolving (LXA and RvD3) agonists","volume":"5","author":"Nunes","year":"2025","journal-title":"ACS Phys. Chem. Au"},{"key":"10.1016\/j.ejpb.2026.115132_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2019.106341","article-title":"The role of lipoxin in regulating tumor immune microenvironments","volume":"144","author":"Zhang","year":"2019","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115132_b0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1021\/acsptsci.9b00097","article-title":"Therapeutic potential of lipoxin A4 in chronic inflammation: focus on cardiometabolic disease","volume":"3","author":"Fu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"19","key":"10.1016\/j.ejpb.2026.115132_b0070","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.7150\/jca.32456","article-title":"Colorectal cancer is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator","volume":"10","author":"Liu","year":"2019","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115132_b0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2015.04.030","article-title":"Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells","volume":"364","author":"Wang","year":"2015","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115132_b0080","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/pharmaceutics17050649","article-title":"Nanostructured lipoxin A4: understanding its biological behavior and impact on Alzheimer\u2019s disease (proof of concept)","volume":"17","author":"Gomes-da-Silva","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115132_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100705","article-title":"Lipoxin A4 yields an electrophilic 15-oxo metabolite that mediates FPR2 receptor-independent anti-inflammatory signaling","volume":"66","author":"Koudelka","year":"2025","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115132_b0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13346-024-01588-9","article-title":"Influence of physico-chemical properties of two lipoxin emulsion-loaded hydrogels on pre-polarized macrophages: a comparative analysis","volume":"15","author":"Guyon","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2026.115132_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.nwnano.2026.100183","article-title":"Advancing drug solubility and precision delivery with next-generation nanocarriers: recent innovations, opportunities, and challenges","volume":"13","author":"Singh","year":"2026","journal-title":"Nano Trends."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115132_b0100","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/bioengineering10101205","article-title":"Use of stromal intervention and exogenous neoantigen vaccination to boost pancreatic cancer chemo-immunotherapy by nanocarriers","volume":"10","author":"Chattopadhyay","year":"2023","journal-title":"Bioengineering (basel)."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115132_b0105","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1038\/s41598-017-10441-8","article-title":"Resolution agonist 15-epi-lipoxin a4 programs early activation of resolving phase in post-myocardial infarction healing","volume":"7","author":"Kain","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2026.115132_b0110","unstructured":"An association between successful engraftment of osteosarcoma patient-derived xenografts and clinicopathological findings. Histol Histopathol. 2020;35(11):1295\u20131307."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115132_b0115","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2106\/00004623-199807000-00011","article-title":"The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma","volume":"80","author":"Wunder","year":"1998","journal-title":"J. Bone Joint Surg. Am."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115132_b0120","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1590\/1413-785220182602186998","article-title":"Patient-derived xenografts as a preclinical model for bone sarcomas","volume":"26","author":"Meohas","year":"2018","journal-title":"Acta Ortop Bras."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115132_b0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/026119291804600508","article-title":"Severity classification of surgical procedures and application of health monitoring strategies in animal research proposals: a retrospective review","volume":"46","author":"Herrmann","year":"2018","journal-title":"Altern. Lab. Anim."},{"key":"10.1016\/j.ejpb.2026.115132_b0130","doi-asserted-by":"crossref","unstructured":"Barja-Fidalgo, C., de Brito, N.\u00e1.l.M., da Costa, H.C., Moretti, J.D. and Sim\u00f5es, R.L. (2020), Lipoxins Selectively Change M2-Like Phenotype Of Tumor associated Macrophages By Changing Their Unique Metabolic Profile And Impairing Tumor Progression. The FASEB Journal, 34: 1-1.https:\/\/doi.org\/10.1096\/fasebj.2020.34.s1.06162.","DOI":"10.1096\/fasebj.2020.34.s1.06162"},{"key":"10.1016\/j.ejpb.2026.115132_b0135","doi-asserted-by":"crossref","unstructured":"Yamamoto S. Biosynthesis and Metabolism of Eicosanoids. Comprehensive Natural Products Chemistry [Internet]. Elsevier; 1999 [cited 2026 Feb 10]. p. 255\u2013271. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780080912837000084.","DOI":"10.1016\/B978-0-08-091283-7.00008-4"},{"key":"10.1016\/j.ejpb.2026.115132_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.949407","article-title":"Therapeutic activity of lipoxin A4 in TiO2-induced arthritis in mice: NF-\u03baB and Nrf2 in synovial fluid leukocytes and neuronal TRPV1 mechanisms","volume":"14","author":"Saraiva-Santos","year":"2023","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115132_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182381","article-title":"Lipoxin A4 encapsulated in PLGA microparticles accelerates wound healing of skin ulcers. Diaz BL, editor","volume":"12","author":"Reis","year":"2017","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.ejpb.2026.115132_b0150","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.7150\/jca.32456","article-title":"Colorectal Cancer is Associated with a Deficiency of Lipoxin A4 , an Endogenous Anti-inflammatory Mediato","volume":"10","author":"Liu","year":"2019","journal-title":"J. Cancer"},{"issue":"8","key":"10.1016\/j.ejpb.2026.115132_b0155","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1158\/1535-7163.MCT-10-0173","article-title":"Lipoxin A4 and its Analogue Suppress the Tumor growth of Transplanted H22 in mice: the Role of Antiangiogenesis","volume":"9","author":"Chen","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2026.115132_b0160","doi-asserted-by":"crossref","unstructured":"E B, H C, S V, et al. Lipoxin A4 a novel therapeutic agent for the treatment of breast cancer metastases. Integr Cancer Sci Therap [Internet]. 2020 [cited 2026 Feb 10];7(3).","DOI":"10.15761\/ICST.1000337"},{"key":"10.1016\/j.ejpb.2026.115132_b0165","doi-asserted-by":"crossref","unstructured":"Zong L, Li J, Chen X, et al. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS\/ERK\/MMP Pathway in Pancreatic Cancer. Tyagi A, editor. Oxidative Medicine and Cellular Longevity. 2016;2016(1):6815727.","DOI":"10.1155\/2016\/6815727"},{"issue":"12","key":"10.1016\/j.ejpb.2026.115132_b0170","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/1535-7163.MCT-21-0414","article-title":"NAP1051, a lipoxin A4 biomimetic analogue, demonstrates antitumor activity against the tumor microenvironment","volume":"20","author":"Dong","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2026.115132_b0175","doi-asserted-by":"crossref","unstructured":"Hoffmann WE, Solter PF. Diagnostic Enzymology of Domestic Animals. Clinical Biochemistry of Domestic Animals [Internet]. Elsevier; 2008 [cited 2026 Feb 10]. p. 351\u2013378. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B978012370491700012X.","DOI":"10.1016\/B978-0-12-370491-7.00012-X"},{"key":"10.1016\/j.ejpb.2026.115132_b0180","doi-asserted-by":"crossref","unstructured":"Anad\u00f3n A, Castellano V, Mart\u00ednez-Larra\u00f1aga MR. Biomarkers in drug safety evaluation. Biomarkers in Toxicology [Internet]. Elsevier; 2014 [cited 2026 Feb 10]. p. 923\u2013945. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780124046306000555.","DOI":"10.1016\/B978-0-12-404630-6.00055-5"},{"key":"10.1016\/j.ejpb.2026.115132_b0185","doi-asserted-by":"crossref","unstructured":"De Vos A, De Troyer R, Stove C. Biomarkers of Alcohol Misuse. Neuroscience of Alcohol [Internet]. Elsevier; 2019 [cited 2026 Feb 10]. p. 557\u2013565. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B978012813125100057X.","DOI":"10.1016\/B978-0-12-813125-1.00057-X"},{"key":"10.1016\/j.ejpb.2026.115132_b0190","doi-asserted-by":"crossref","unstructured":"Arnold DR, Kwiterovich PO. CHOLESTEROL | Absorption, Function, and Metabolism. Encyclopedia of Food Sciences and Nutrition [Internet]. Elsevier; 2003 [cited 2026 Feb 10]. p. 1226\u20131237. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B012227055X00225X.","DOI":"10.1016\/B0-12-227055-X\/00225-X"},{"key":"10.1016\/j.ejpb.2026.115132_b0195","doi-asserted-by":"crossref","unstructured":"Vu\u010di\u0107 V, Cvetkovi\u0107 Z. Cholesterol: Absorption, Function and Metabolism. Encyclopedia of Food and Health [Internet]. Elsevier; 2016 [cited 2026 Feb 10]. p. 47\u201352. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780123849472001513.","DOI":"10.1016\/B978-0-12-384947-2.00151-3"},{"key":"10.1016\/j.ejpb.2026.115132_b0200","doi-asserted-by":"crossref","unstructured":"Mukherjee PK, Harwansh RK, Bahadur S, et al. Enzyme inhibition assay for metabolic disorders\u2014exploring leads from medicinal plants. Animal Biotechnology [Internet]. Elsevier; 2020 [cited 2026 Feb 10]. p. 631\u2013653. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128117101000331.","DOI":"10.1016\/B978-0-12-811710-1.00033-1"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115132_b0205","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1096\/fj.12-208249","article-title":"Lipoxin A4 attenuates adipose inflammation","volume":"26","author":"B\u00f6rgeson","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.ejpb.2026.115132_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.biortech.2022.127390","article-title":"Understanding the management of household food waste and its engineering for sustainable valorization- a state-of-the-art review","volume":"358","author":"Haldar","year":"2022","journal-title":"Bioresour. Technol."},{"key":"10.1016\/j.ejpb.2026.115132_b0215","doi-asserted-by":"crossref","unstructured":"Taniguchi H, Honnda Y. Amylases. Encyclopedia of Microbiology [Internet]. Elsevier; 2009 [cited 2026 Feb 10]. p. 159\u2013173. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780123739445001309.","DOI":"10.1016\/B978-012373944-5.00130-9"},{"key":"10.1016\/j.ejpb.2026.115132_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","article-title":"Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs","volume":"500","author":"Chen","year":"2021","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115132_b0225","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bph.15713","article-title":"Osteosarcoma mechanobiology and therapeutic targets","volume":"179","author":"Shoaib","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115132_b0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.path.2025.01.009","article-title":"Osteosarcoma","volume":"18","author":"Gross","year":"2025","journal-title":"Surg. Pathol. Clin."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115132_b0235","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s12015-022-10426-9","article-title":"Cancer stem cells and the tumor microenvironment: targeting the critical crosstalk through nanocarrier systems","volume":"18","author":"Nayak","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"issue":"13","key":"10.1016\/j.ejpb.2026.115132_b0240","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.2174\/1389450119666180131105822","article-title":"Nanocarrier based advances in drug delivery to tumor: an overview","volume":"19","author":"Jain","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115132_b0245","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/nano12071146","article-title":"Lipid-based nano-sized cargos as a promising strategy in bone complications: a review","volume":"12","author":"Hallan","year":"2022","journal-title":"Nanomaterials (basel)."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2026.115132_b0250","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ijpharm.2017.07.039","article-title":"Nano lipid-drug conjugate: an integrated review","volume":"529","author":"Adhikari","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115132_b0255","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41419-019-1806-8","article-title":"Nano-bio interactions: a neutrophil-centric view","volume":"10","author":"Keshavan","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejpb.2026.115132_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114318","article-title":"Nano-bio interactions: a major principle in the dynamic biological processes of nano-assemblies","volume":"186","author":"Liu","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115132_b0265","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2174\/1567201819666220324092933","article-title":"Functionalized nanostructured bioactive carriers: nanoliposomes, quantum dots, tocosome, and theranostic approach","volume":"19","author":"Mehrarya","year":"2022","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115132_b0270","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115132_b0275","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ijc.30424","article-title":"Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression","volume":"140","author":"Sim\u00f5es","year":"2017","journal-title":"Int. J. Cancer"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:41:32Z","timestamp":1790109692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"alternative-id":["S0939641126001530"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115132","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoxin A4 (LXA4) versus Nanolipoxin A4 (Nano-LXA4) for osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115132"}}